Mov Disord Vol 38, Suppl 1 Archives - Page 123 of 186 - MDS Abstracts

2023 International Congress
Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
J. Suescun, T. Ellmore, C. Adams, V. Thyne, E. Tharp, S. Chandra, C. Green, R. Shastri, J. Saltarrelli, M. Schiess (Houston, USA)
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…
2023 International Congress
Analysis of the relationship between acoustic measures and VHI score
Y. Manor, Y. Kochetkov, Y. Hauptman, D. Shpunt, A. Zait, T. Gurevich (Tel Aviv, Israel)
Objective: To examine whether there is a relationship between acoustic measurements extracted from audio recordings of sustained vowel /a/ of PWP and their VHI scores.…
2023 International Congress
Comparison in the disability level according to WHODAS 2 between people living with Early and Late Onset Parkinson’s Disease
M E. Pimentel Piemonte, K. Costa Nobrega, I. Silva Nascimento, B. Antunes Souza, I. Carneiro Barone, G. Checchio, V. Pereira Ponciano, C. Cerveira Paula, A. Nunes Possani, N. Cardos Penha (Sao Paulo, Brazil)
Objective: To compare disability levels according to WHODAS-2 between people living with EOPD and people living with LOPD. Background: Although Parkinson's disease (PD) is more…
2023 International Congress
An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials
R. Freeman, I. Biaggioni, L. Norcliffe-Kaufmann, T. Guerin, R. Vickery, L. Manzanares, V. Iodice, M. Rudzińska-Bar, M. Pellecchia, H. Kaufmann (Boston, USA)
Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…
2023 International Congress
Association of real-world wearable mobility measures with Parkinson’s disease severity and disease progression
A. Mirelman, J. Volkov, A. Solomon, E. Gazit, A. Nieuwboer, S. Del Din, L. Rochester, L. Avanzino, E. Pelosin, B. Bloem, U. Della Croce, A. Cereatti, A. Thaler, J. Shirvan, J. Cedarbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)
Objective: To identify real-world mobility measures that are most reflective of PD severity and to assess their sensitivity to changes over time, as compared to…
2023 International Congress
Training an APRN in movement disorders: lessons learned
M. Burnett, A. Guggenmos (Omaha, USA)
Objective: To discuss the development and implementation of a training program of a neurology-naïve Advanced Practice Registered Nurse (APRN) into a small academic movement practice…
2023 International Congress
Online recruitment and retention in the Parkinson’s Progression Markers Initiative (PPMI)
C. Tanner, E. Brown, L. Chahine, D. Weintraub, R. Dobkin, W. Poewe, E. Tolosa, C. Marras, S. Schade, C. Coffey, M. Korell, C. Stanley, J. Valdeverde Twiggs, M. Kuhl, K. Fabrizio, S. Chowdhury, T. Sherer, A. Siderowf, T. Simuni, K. Marek (SAN FRANCISCO, USA)
Objective: To describe participants and retention in the longitudinal PPMI Online cohort Background: The overall PPMI aim of biomarker identification to enable therapeutic development is…
2023 International Congress
Understanding rehabilitation care utilization in Parkinson’s disease
J. Goldman, T. Williams-Wood, H. Peirce, D. Merkitch (Chicago, USA)
Objective: The aim of our study was to examine experiences with rehabilitation services by people with Parkinson’s disease (PD) and their care partners (CP). Background:…
2023 International Congress
Peripheral Synucleinopathy in Essential Tremor Plus Patients with Parkinsonian Features and Normal Dopamine Transporter Imaging
VG. Evidente, T. Levine, D. Evidente, R. Freeman, C. Gibbons (Scottsdale, USA)
Objective: To describe results of skin biopsy for phosphorylated alpha-synuclein (P-SYN) in patients with essential tremor (ET) with parkinsonism. Background: Patients with longstanding ET may…
2023 International Congress
Impaired Mitophagy and Mitochondrial-energetics in Parkinson’s disease: A Novel Therapeutic Strategy of Re-tasking Felodipine
A. Roy, S. Choudhury, R. Banerjee, A. Costa, P. Sheshadri, M. Duchen, S. Dey, H. Kumar (Kolkata, India)
Objective: This study aimed to validate impairment of mitochondrial energetics and mitophagy in PD and the action of felodipine in restoring altered Mitochondria-lysosome (Mito-Lyso) homeostasis.…